Monarch Capital Management Inc Gilead Sciences, Inc. Transaction History

Monarch Capital Management Inc

$353 Million
Q1 2025

A detailed history of Monarch Capital Management Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Monarch Capital Management Inc holds 44,689 shares of GILD stock, worth $4.88 Million. This represents 1.42% of its overall portfolio holdings.

Number of Shares

44,689

Previous 47,079 5.08%

Holding current value

$4.88 Million

Previous $4.35 Million 15.16%

% of portfolio

1.42%

Previous 1.21%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 15, 2025	SELL	$89.14 - $117.41 $213,044 - $280,609	-2,390 Reduced 5.08%	44,689 $5.01 Million
Q4 2024 Jan 15, 2025	SELL	$83.95 - $97.9 $70,518 - $82,236	-840 Reduced 1.75%	47,079 $4.35 Million
Q3 2024 Oct 16, 2024	SELL	$66.59 - $83.99 $19,777 - $24,945	-297 Reduced 0.62%	47,919 $4.02 Million
Q2 2024 Jul 24, 2024	SELL	$63.15 - $72.88 $42,815 - $49,412	-678 Reduced 1.39%	48,216 $3.31 Million
Q1 2024 Apr 25, 2024	SELL	$71.58 - $87.29 $23,692 - $28,892	-331 Reduced 0.67%	48,894 $3.58 Million
Q4 2023 Jan 17, 2024	SELL	$73.27 - $83.09 $58,469 - $66,305	-798 Reduced 1.6%	49,225 $3.99 Million
Q3 2023 Nov 02, 2023	SELL	$73.94 - $80.67 $70,612 - $77,039	-955 Reduced 1.87%	50,023 $3.75 Million
Q2 2023 Aug 01, 2023	SELL	$76.01 - $86.7 $109,682 - $125,108	-1,443 Reduced 2.75%	50,978 $3.93 Million
Q1 2023 Apr 25, 2023	SELL	$77.31 - $88.08 $60,301 - $68,702	-780 Reduced 1.47%	52,421 $4.35 Million
Q4 2022 Jan 26, 2023	SELL	$62.32 - $89.47 $325,310 - $467,033	-5,220 Reduced 8.94%	53,201 $0
Q3 2022 Oct 20, 2022	SELL	$59.54 - $68.01 $85,023 - $97,118	-1,428 Reduced 2.39%	58,421 $3.6 Million
Q2 2022 Jul 20, 2022	SELL	$57.72 - $65.01 $5,194 - $5,850	-90 Reduced 0.15%	59,849 $3.7 Million
Q1 2022 Apr 20, 2022	SELL	$57.92 - $72.58 $40,196 - $50,370	-694 Reduced 1.14%	59,939 $3.56 Million
Q4 2021 Jan 19, 2022	BUY	$64.88 - $73.64 $25,952 - $29,456	400 Added 0.66%	60,633 $4.4 Million
Q3 2021 Nov 04, 2021	SELL	$67.69 - $73.03 $292,420 - $315,489	-4,320 Reduced 6.69%	60,233 $4.21 Million
Q2 2021 Jul 22, 2021	BUY	$63.47 - $69.35 $317 - $346	5 Added 0.01%	64,553 $4.45 Million
Q1 2021 Apr 27, 2021	SELL	$60.0 - $68.46 $169,260 - $193,125	-2,821 Reduced 4.19%	64,548 $4.17 Million
Q4 2020 Jan 26, 2021	BUY	$56.65 - $64.55 $106,955 - $121,870	1,888 Added 2.88%	67,369 $3.93 Million
Q3 2020 Oct 22, 2020	BUY	$62.1 - $78.08 $46,388 - $58,325	747 Added 1.15%	65,481 $4.14 Million
Q2 2020 Jul 23, 2020	SELL	$72.34 - $84.0 $172,313 - $200,088	-2,382 Reduced 3.55%	64,734 $4.98 Million
Q1 2020 Apr 30, 2020	BUY	$62.63 - $80.22 $546,634 - $700,160	8,728 Added 14.95%	67,116 $5.02 Million
Q4 2019 Jan 28, 2020	BUY	$61.62 - $67.78 $172,536 - $189,784	2,800 Added 5.04%	58,388 $3.79 Million
Q3 2019 Oct 30, 2019	BUY	$62.51 - $69.0 $41,756 - $46,092	668 Added 1.22%	55,588 $3.52 Million
Q2 2019 Jul 31, 2019	BUY	$61.87 - $69.38 $92,248 - $103,445	1,491 Added 2.79%	54,920 $3.71 Million
Q1 2019 May 01, 2019	BUY	$62.53 - $70.05 $226,483 - $253,721	3,622 Added 7.27%	53,429 $3.47 Million
Q4 2018 Jan 23, 2019	SELL	$60.54 - $79.0 $180,409 - $235,420	-2,980 Reduced 5.65%	49,807 $3.12 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $154,321 - $170,861	-2,165 Reduced 3.94%	52,787 $4.08 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $13,170 - $15,363	203 Added 0.37%	54,952 $3.89 Million
Q1 2018 Apr 18, 2018	BUY	$72.84 - $88.8 $59,000 - $71,928	810 Added 1.5%	54,749 $4.13 Million
Q4 2017 Jan 31, 2018	SELL	$71.15 - $83.52 $115,263 - $135,302	-1,620 Reduced 2.92%	53,939 $3.86 Million
Q3 2017 Oct 18, 2017	BUY	$72.11 - $85.47 $4.01 Million - $4.75 Million	55,559	55,559 $4.5 Million

Others Institutions Holding GILD

# of Institutions

2,285

Shares Held

997M

Call Options Held

9.62M

Put Options Held

10M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $137B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Monarch Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Monarch Capital Management Inc with notifications on news.

Account

Monarch Capital Management Inc Gilead Sciences, Inc. Transaction History